ACT Advisors’s Rallybio RLYB Stock Holding History

ACT Advisors’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,644	Closed	-$9.02K	–	82
2025 Q4	$9.02K	Buy	+1,644	New	+$8.46K	﹤0.01%	65

Other funds holding RLYB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

ACT Advisors's RLYB Position: Q1 2026 in Review

ACT Advisors sold out of Rallybio (RLYB) in Q1 2026, closing a stake of 1,644 shares — an estimated $9.02K sold.

ACT Advisors first reported a position in RLYB in Q4 2025 and held it in 1 quarter. The position peaked at $9.02K in Q4 2025. 38 funds tracked by Wall St. Rank hold RLYB as of Q1 2026.

ACT Advisors reported no remaining Rallybio position as of Q1 2026 after selling out during the quarter.
ACT Advisors sold 1,644 Rallybio shares in Q1 2026, an estimated $9.02K.
ACT Advisors first reported a position in Rallybio in Q4 2025 and held it in 1 quarter.
ACT Advisors's Rallybio position peaked at $9.02K in Q4 2025.
38 funds tracked by Wall St. Rank held Rallybio as of Q1 2026.

Based on ACT Advisors's 13F filing for Q1 2026, filed 14 Apr 2026.